ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: PP22 • ACR Convergence 2022

    Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance

    Natasha Trehan1 and Laurie Proulx2, 1Take a Pain Check Foundation, Markham, ON, Canada, 2Canadian Arthritis Patient Alliance, Ottawa, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis is a chronic disease that affects a child's school life and relationships, creating social isolation for youth and young adults. Take…
  • Abstract Number: PP10 • ACR Convergence 2022

    How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology

    Brooklyn Johnson1 and Kathleen Collins2, 1Memphis, TN, 2LeBonheur Children's Hospital, Memphis, TN

    Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
  • Abstract Number: PP24 • ACR Convergence 2022

    Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp

    Kaye Anderson1, Kristine Carandang2 and Courtney Wells3, 1Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, 2Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 3University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
  • Abstract Number: PP06 • ACR Convergence 2022

    Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired

    Lawrence Phillips, Noblesville, IN

    Background/Purpose: I was diagnosed with rheumatoid arthritis (RA) in 1999. In 2015 and 2019, two surgeons independently diagnosed me with ankylosing spondylitis (AS) following two…
  • Abstract Number: PP20 • ACR Convergence 2022

    ‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease

    Melissa Allman, Michigan State University, Meridian Charter Township, MI

    Background/Purpose: Trauma can have profound detrimental influences on our health and well-being. I am tangibly familiar with how trauma can impact the individual due to…
  • Abstract Number: PP04 • ACR Convergence 2022

    Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building

    Kara Wada, The Ohio State University, Columbus, OH

    Background/Purpose: After years of ignoring my dry eyes and mouth, unrelenting fatigue, and body pain, an off-the-cuff comment from my dental hygienist finally pushed me…
  • Abstract Number: PP12 • ACR Convergence 2022

    We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board

    Zucy Almonacid1, Wigna Cruz2, Francisca Garcia3, Teresa Hernandez4, Velia Martinez5, Patricia Mattos3, Mario Mutis6 and Denise Serrano7, 1Hicsville, NY, 2Juan Diaz, PR, 3Lake Worth, FL, 4Greenacres, FL, 5Guaynabo, PR, 6Fort Pierce, FL, 7Toa Alto, PR

    Background/Purpose: Each of us has been diagnosed with rheumatoid arthritis (RA), from as recently as one year ago to as long as 20 years ago.…
  • Abstract Number: 2188 • ACR Convergence 2022

    The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial

    Kristine Latocha1, Katrine Loeppenthin2, Mikkel Østergaard3, poul jennum4, Merete L Hetland5, Henrik Rogind6, Tine Lundbak6, Julie Midtgaard7, Robin Christensen8 and Bente Esbensen5, 1Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, 2Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 3Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 4Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, 5Rigshospitalet, Glostrup, Denmark, 6Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, 7Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 8Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark

    Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…
  • Abstract Number: 2187 • ACR Convergence 2022

    Decision-Making Around Vaccination and Other Public Health Measures During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis

    Jenny leese1, Stephanie Therrien2, Smruthi Ramachandran3, Catherine L. Backman3, Jasmin Ma4, Kelly English5, Eileen Davidson6, Shanon McQuitty7, Alison Hoens5, Cheryl Koehn8, James Gavin9, jo Adams9 and Linda Li3, 1University of Ottawa, Ottawa, ON, Canada, 2Arthritis Research Canada, Vancouver, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, 5Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, 6Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, 7Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, 8Arthritis Consumer Experts, Vancouver, BC, Canada, 9University of Southampton, Southampton, United Kingdom

    Background/Purpose: The spectrum of individual decisions about adopting public health measures (e.g., vaccination programs, physical distancing, mask wearing) to reduce COVID-19 transmission has important implications…
  • Abstract Number: PP03 • ACR Convergence 2022

    To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: In November 1999, the Institute of Medicine issued a press release announcing publication of To Err is Human: Building a Safer Health System (Kohn…
  • Abstract Number: 2186 • ACR Convergence 2022

    Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs

    Sokratis Apostolidis1, Paulina Coutifaris2, Mark Painter3, Ajinkya Pattekar2, Rishi Goel1, divij mathew2, Wenzhao Meng2, Kevin Wang2, Bria Fulmer2, Angela Corrigan2, Kendall Lundgreen2, Elizabeth Drapeau2, Derek Oldridge2, Josephine Giles2, Amy Baxter2, Sasikanth Manne2, Michelle Mckeague2, Ahron Flowers2, Oliva Kuthuru2, Sherea Long2, Jeanette Dougherty2, Sigrid Gouma2, Justine Williams2, Maura McLaughlin2, Sharon Adamski2, Alba Grifoni4, Daniela Weiskopf4, Alessandro Sette4, Scott Hensley2, Paul Bates2, Eline Luning Prak1, Laura Vella2, Giorgos Karakousis2, Ravi Amaravadi2, Suzanne McGettigan2, Kristin Kreider2, Tara Mitchell2, Allison Greenplate2, Lynn Schuchter2, Alexander Huang2 and E. John Wherry1, 1University of Pennsylvania, Philadelphia, PA, 2UPenn, Philadelphia, 3UPenn, Philadelphia, PA, 4LJI, La Jolla

    Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
  • Abstract Number: 1805 • ACR Convergence 2022

    Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares

    Natalie McCormick1, Chio Yokose2, Minna Kohler3, Janeth Yinh1, Clara Chen4, Tuhina Neogi5, Tony Merriman6, kenneth saag7, Yuqing Zhang8 and Hyon Choi9, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Boston University School of Public Health, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6University of Otago, Dunedin, New Zealand, 7University of Alabama at Birmingham, Birmingham, AL, 8Massachusetts General Hospital, Quincy, MA, 9MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: Habitual fructose-rich beverage intake has been associated with increased serum urate (SU) levels and prevalent and incident gout. This is likely because fructose induces…
  • Abstract Number: 2182 • ACR Convergence 2022

    mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis

    Xiaowei Zhang1, Antony Jozic1, Pingfang Song1, Qiang Xu2, Xiaofei Shi3, Hong Wang4, Lindsey Bishop1, Hillary Struthers1, John Rutledge5, Shuang Chen1, Fei Xu1, Meaghan Hancock1, Daocheng Zhu6, Gaurav Sahay1 and Cong-Qiu Chu1, 1Oregon Health & Science University, Portland, OR, 2Guangzhou University of Chinese Medicine, Guangzhou, China, 3Henan University of Science and Technology, Luoyang, China, 4Wenzhou Medical University, Wenzhou, China, 5Portland VA Research Foundation, Portland, 6Shanghai Kexin Biotechnology, Shanghai, China

    Background/Purpose: Synovial fibroblasts in patients with rheumatoid arthritis (RA) contribute substantially to the perpetuation of synovitis and invasion to cartilage and bone, and have been…
  • Abstract Number: 1803 • ACR Convergence 2022

    Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials

    Michael Pillinger1, Katie Obermeyer2, Lissa Padnick-Silver2 and Brian LaMoreaux2, 1NYU Grossman School of Medicine, New York, NY, 2Horizon Therapeutics plc, Deerfield, IL

    Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…
  • Abstract Number: 1806 • ACR Convergence 2022

    Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing

    Naomi Schlesinger1, Lissa Padnick-Silver2, Katie Obermeyer2 and Brian LaMoreaux2, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Horizon Therapeutics plc, Deerfield, IL

    Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
  • « Previous Page
  • 1
  • …
  • 507
  • 508
  • 509
  • 510
  • 511
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology